For patients with CINV, RINV, or PONV*

ZUPLENZ HELPS
PREVENT NAUSEA
AND VOMITING
"ON THE GO"

Contains the #1 prescribed agent for prevention of nausea and vomiting1

ZUPLENZ provides an alternative to pills in a thin, minty film strip.

  • ZUPLENZ is contraindicated in patients who are concomitantly using apomorphine. Concomitant use of ZUPLENZ and apomorphine may result in profound hypotension and loss of consciousness

Designed for a smoother
treatment journey

Film strips are portable, flexible, and dissolve in seconds.2,3


  • ZUPLENZ is contraindicated in patients with a known hypersensitivity to ondansetron as anaphylactic reactions have been known to occur

INDICATIONS AND USAGE

ZUPLENZ is a 5-HT3 receptor antagonist indicated for prevention of nausea and vomiting associated with highly emetogenic chemotherapy in adults; initial and repeat courses of moderately emetogenic chemotherapy in adults and children aged 4 and up; following total body irradiation, single-high-dose fraction of radiotherapy to the abdomen, or daily fractions to the abdomen in adults; and post-operatively in adults.

Prescribe with confidence with the Fortovia Direct Rx Access Program

  • Affordable access for your patients
    • All eligible patients pay $0 out-of-pocket costs for 1 month of therapy†
    • Patients can receive free door-to-door service when healthcare professionals order directly from a Fortovia Direct Rx specialty pharmacy
  • Streamlined Patient Assistance Program for most noneligible patients

ZUPLENZ helps
prevent nausea
and vomiting in
patients receiving
some types of
cancer therapy1

Learn More

Affordable
access for
patients
with
CINV/RINV/PONV

Learn More

 
Dosing
for
ZUPLENZ
 

Learn More

Contact us
for more
information
about
ZUPLENZ

Contact Us

*CINV, chemotherapy-induced nausea and vomiting; RINV, radiation-induced nausea and vomiting; PONV, postoperative nausea and vomiting.

†Terms and Conditions: Certain patients in Federal programs may not qualify. Qualified patients will pay $0 per ZUPLENZ prescription. After a maximum reimbursement allowance, any remaining costs will be the responsibility of the patient. Co-pay assistance is not valid for prescriptions reimbursed, in whole or in part, under Medicaid, Medicare, including Medicare Advantage and Part D prescription drug plans, or any other federal or state program (including state pharmaceutical assistance programs) or where prohibited, taxed, or otherwise restricted. Fortovia Therapeutics Inc. reserves the right to rescind, revoke, or amend this offer without notice. Patients understand and agree to comply with the terms and conditions of this offer as set forth here.

References

  1. Symphony Health Solutions
  2. ZUPLENZ (package insert). Midatech Pharma US Inc. 2016.
  3. Dadey E. Bioequivalence of ondansetron oral soluble film 8 mg (ZUPLENZ) and ondansetron orally disintegrating tablets 8 mg (ZOFRAN) in healthy adults. Am J Ther. 2015;22(2):90-97.

IMPORTANT SAFETY INFORMATION

  • ZUPLENZ is contraindicated in patients who are concomitantly using apomorphine. Concomitant use of ZUPLENZ and apomorphine may result in profound hypotension and loss of consciousness.
  • ZUPLENZ is contraindicated in patients with a known hypersensitivity to ondansetron as anaphylactic reactions have been known to occur.
  • ZUPLENZ may mask a progressive ileus and/or gastric distention in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting.
  • Patients with severe hepatic impairment (Child-Pugh score of 10 or greater) should not receive more than 8mg of ZUPLENZ per day due to a reduction in drug clearance.
  • Patients receiving ondansetron have experienced ECG changes including QT interval prolongation, including cases of Torsade de Pointes. ZUPLENZ should be used with caution in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medications that can lead to QT interval prolongation. ZUPLENZ should not be used in patients with congenital long QT syndrome.
  • Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Discontinue using ZUPLENZ at the first sign of hypersensitivity.
  • Serotonin syndrome has been reported in patients taking 5-HT3 receptor agonists, with most cases being reported in patients taking serotonergic drugs concomitantly with ondansetron. Some of these cases were fatal. Some reported cases of serotonin syndrome occurred in patients who have overdosed on ondansetron alone.
  • ZUPLENZ is Pregnancy Category B and should only be used during pregnancy for the approved indications if clearly needed.
  • The most common adverse events occurring in clinical trials of ondansetron in CINV and RINV patients included: headache, malaise/fatigue, constipation and diarrhea. The most common adverse events occurring in a clinical trial of ondansetron in PONV included: headache, hypoxia, pyrexia, dizziness, gynecological disorder, anxiety/agitation, urinary retention, and pruritus. In the PONV study, only headache was statistically more significant than adverse events seen in placebo patients.
  • ZUPLENZ has been shown to be safe and effective for use in pediatric patients 4 years of age and older who are undergoing moderately emetogenic cancer chemotherapy. It has not been proven safe and effective in any other pediatric indication.

You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch, or call Fortovia at 1-855-273-0468 for medical inquiries.

Please see full Prescribing Information.

Click to expand Click to collapse

IMPORTANT SAFETY INFORMATION

  • ZUPLENZ is contraindicated in patients who are concomitantly using apomorphine. Concomitant use of ZUPLENZ and apomorphine may result in profound hypotension and loss of consciousness.
  • ZUPLENZ is contraindicated in patients with a known hypersensitivity to ondansetron as anaphylactic reactions have been known to occur.
  • ZUPLENZ may mask a progressive ileus and/or gastric distention in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting.
  • Patients with severe hepatic impairment (Child-Pugh score of 10 or greater) should not receive more than 8mg of ZUPLENZ per day due to a reduction in drug clearance.
  • Patients receiving ondansetron have experienced ECG changes including QT interval prolongation, including cases of Torsade de Pointes. ZUPLENZ should be used with caution in patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medications that can lead to QT interval prolongation. ZUPLENZ should not be used in patients with congenital long QT syndrome.
  • Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Discontinue using ZUPLENZ at the first sign of hypersensitivity.
  • Serotonin syndrome has been reported in patients taking 5-HT3 receptor agonists, with most cases being reported in patients taking serotonergic drugs concomitantly with ondansetron. Some of these cases were fatal. Some reported cases of serotonin syndrome occurred in patients who have overdosed on ondansetron alone.
  • ZUPLENZ is Pregnancy Category B and should only be used during pregnancy for the approved indications if clearly needed.
  • The most common adverse events occurring in clinical trials of ondansetron in CINV and RINV patients included: headache, malaise/fatigue, constipation and diarrhea. The most common adverse events occurring in a clinical trial of ondansetron in PONV included: headache, hypoxia, pyrexia, dizziness, gynecological disorder, anxiety/agitation, urinary retention, and pruritus. In the PONV study, only headache was statistically more significant than adverse events seen in placebo patients.
  • ZUPLENZ has been shown to be safe and effective for use in pediatric patients 4 years of age and older who are undergoing moderately emetogenic cancer chemotherapy. It has not been proven safe and effective in any other pediatric indication.

You are encouraged to report negative side effects of prescription medical products to the FDA.
Visit www.fda.gov/safety/medwatch, or call Fortovia at 1-855-273-0468 for medical inquiries.

Please see full Prescribing Information.